Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Hodgkin Disease × Radiotherapy × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 1

Interventions

Brentuximab Vedotin 2 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 Vinblastine 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Doxorubicin 1 Dacarbazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting

994 enrolled 11 charts 3 FDA

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡